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Angiotensin II-induced 
hypertension in rats is only 
transiently accompanied by lower 
renal oxygenation
Tonja. W. Emans1,2, Daniela Patinha3, Jaap. A. Joles  2, Maarten. P. Koeners3, Ben. J. Janssen4 
& C. T. Paul Krediet1
Activation of the renin-angiotensin system may initiate chronic kidney disease. We hypothesised that 
renal hypoxia is a consequence of hemodynamic changes induced by angiotensin II and occurs prior 
to development of severe renal damage. Male Sprague-Dawley rats were infused continuously with 
angiotensin II (350 ng/kg/min) for 8 days. Mean arterial pressure (n = 5), cortical (n = 6) and medullary 
(n = 7) oxygenation (pO2) were continuously recorded by telemetry and renal tissue injury was scored. 
Angiotensin II increased arterial pressure gradually to 150 ± 18 mmHg. This was associated with 
transient reduction of oxygen levels in renal cortex (by 18 ± 2%) and medulla (by 17 ± 6%) at 10 ± 2 and 
6 ± 1 hours, respectively after starting infusion. Thereafter oxygen levels normalised to pre-infusion 
levels and were maintained during the remainder of the infusion period. In rats receiving angiotensin 
II, adding losartan to drinking water (300 mg/L) only induced transient increase in renal oxygenation, 
despite normalisation of arterial pressure. In rats, renal hypoxia is only a transient phenomenon during 
initiation of angiotensin II-induced hypertension.
Disturbed renal oxygenation has been hypothesised as an aggravating factor during chronic kidney disease 
(CKD), by activation of local intrarenal pro-inflammatory and pro-fibrotic processes1,2. According to the hypoxia 
in CKD hypothesis as originally coined by Fine et al., hypoxia occurs before the establishment of renal histolog-
ical damage. This suggests that, although there are several causes to renal damage, hypoxia is a common denom-
inator in development of renal damage and may therefore be a new target for treatment. Hypoxia occurs when 
oxygen delivery and consumption are unbalanced. Glomerular hyperfiltration and subsequent increased tubular 
solute reabsorption increases oxygen consumption relative to the blood flow to the nephron. This cascade leads to 
hypoxia in the tubulo-interstitial compartment and should be detectable at an early stage of disease3.
In spontaneously hypertensive rats, reduced renal oxygenation was measured by ultra-microelectrodes4. In a 
remnant kidney model renal cortical hypoxia was identified by pimonidazole staining after 4 days5. In a progres-
sive model of rat glomerulonephritis, wherein uninephrectomy was combined with repeated anti-Thy-1 antibody 
injections, hypoxia occurred from the first week on6. These findings imply that hypoxia indeed occurs early after 
initiation of mild renal damage and contributes to disease progression. Experimental reduction in oxygen deliv-
ery in isolated perfused rat kidneys exacerbates renal damage7, and an increase in renal oxygen consumption by 
administration of dinitrophenol caused proteinuria and infiltration of inflammatory cells8. In humans, reduced 
oxygenation levels were correlated to CKD severity9. However, so far, evidence of hypoxia in kidney disease 
has been based on indirect measurements or under anesthesia at a single time point. Direct tissue oxygenation 
(pO2) measurements determining hypoxia before the onset of chronic renal disease are lacking. In humans, renal 
oxygenation measurements are only possible by indirect measurements, such as blood-oxygen-level dependent 
(BOLD) magnetic resonance imaging10–12. Therefore, it is difficult to draw conclusions regarding the effect of 
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hypoxia in time. Deciphering a potential role of tissue hypoxia in the initiation of renal disease asks for meas-
urement techniques that are not restricted in time and can be done in the absence of anesthesia, which impair 
renal hemodynamics13. Renal function needs to recover from minor implantation surgery as well13. Therefore, in 
the present study we used an oxygen telemetry system to record kidney oxygenation 1) continuously 2) in awake 
animals throughout the experiment, and 3) after at least one week of recovery from implantation14,15.
A proposed link between hypoxia and initial renal changes within kidney disease is activation of the 
Renin-Angiotensin-System (RAS). Administration of an angiotensin-converting-enzyme (ACE) inhibitor or 
angiotensin receptor blocker (ARB) increased cortical oxygenation, measured by protoporphyrin phospho-
rescence, in anesthetised healthy rats16. In 5/6 nephrectomised rats, ARB administration attenuated hypoxia, 
assessed by pimonidazole staining5. These observations suggest that RAS activation is associated with early phase 
oxygenation changes. The RAS is a potent regulator of intrarenal hemodynamics and its activation is an acknowl-
edged pathophysiological factor in the progression of kidney disease in humans17 and rats18. In rats, angiotensin 
II (AngII) infusion causes systemic hypertension, increases glomerular capillary pressure (and increases filtra-
tion fraction), and reduces renal blood flow (RBF)19. While the magnitude of these effects are dependent on the 
genetic background20 AngII-induced hypertensive nephrosclerosis, renal injury typically develops over time17, 
and usually becomes evident after about 7 days21. Previously, we observed that AngII infusion acutely decreased 
renal cortical oxygenation in rats15. That study was not designed to test for long-term consequences of AngII 
infusion.
In the present study, we used chronic AngII infusion to identify hypoxia before the establishment of renal 
damage. Oxygenation is different in renal cortex and medulla, due to structural and functional differences in 
relation to oxygen delivery, consumption and shunting22. Besides, cortical and medullary oxygenation responded 
differently to acute AngII infusions in awake sheep23. Therefore, we measured pO2 in both cortex and medulla. 
We hypothesised that renal hypoxia develops in cortex and medulla in AngII-induced hypertension prior to 
glomerulosclerosis and that this would be reversible by AngII type 1 (AT1) receptor blockade. In addition we 
analyzed the diurnal fluctuations in pO2 during AngII infusion. Under physiological conditions, we observed 
circadian rhythmicity in rat renal cortex and medulla24. Intrarenal RAS and mean arterial pressure (MAP) have 
circadian rhythmicity, which is associated with renal damage when disturbed25. To our knowledge, the effects of 
AngII infusion on circadian rhythm of renal oxygenation are unknown.
Methods
Animals. Male Sprague-Dawley rats (Charles River), weighing 300 to 350 g were co-housed in pairs. Animals 
were kept on a 12 h light/dark cycle with lights-on at 6am, and lights-off at 6 pm and allowed access to water and 
standard rat chow ad libitum. Temperature and humidity in the room were controlled at 21 degrees Celsius and 
45%, respectively. All procedures were approved by the Animal Ethics Committee of Utrecht (DEC nr. 2014.
II.03.015) and were in accordance with the Dutch Codes of Practice for the Care and Use of Animals for Scientific 
Purposes or with the United Kingdom Animals (Scientific Procedures) Act 1986 and associated guidelines, under 
licence to the Home Office.
Surgical procedures for chronic kidney pO2 and MAP measurements. Oxygen sensitive carbon 
paste electrodes were attached to telemeters (TR57Y, Kaha Sciences, New Zealand) and calibrated for linearity 
before implantation14,26. In short, anaesthesia was induced with 5% isoflurane and maintained during spontane-
ous breathing of isoflurane at 2–3% added to 100% O2. The right kidney was exposed by laparotomy and elec-
trodes (with telemeters in off mode) were implanted as described in detail26. The tip of the electrodes was placed 
in the cortex or medulla, at appropriate depths (0.8–1.2 or 3.5–4.0 mm, respectively). Implantation depth was 
verified at the end of protocol. The body of telemeter was secured on the inner abdominal muscle. Rats were kept 
on a warm pad separately overnight. After 24 h of recovery, the animal cage was placed on a Smartpad (TR181, 
Kaha Sciences) to start recording of renal tissue pO2.
In other rats, MAP was recorded by telemetry (TRM54P, Kaha Sciences) by placing the pressure tip in the 
abdominal aorta. The abdominal aorta was exposed by laparotomy using similar anaesthetic procedures. Pressure 
catheters were inserted in the abdominal aorta through a small hole made just above the bifurcation. After 24 h 
of recovery, the animal cage was placed on an external receiver pad (TR181, Kaha Sciences) to start recording of 
MAP. Since this is an invasive technique and may be associated with impaired renal function due to the implan-
tation and procedures per se, a considerable period of recovery was allowed. In rats instrumented with oxygen 
telemeters systolic blood pressure (SBP) was measured by tail-cuff plethysmography.
Chronic AngII infusion and AT1-blockade. Baseline MAP and pO2 levels were recorded for at least 5 
days before AngII was administered. Osmotic pumps (Model 1002, Alzet, estimated flowrate 0.25 µl/h for 8 days) 
were filled with an AngII solution (30 mg/ml) in sterile NaCl with 0.01 N AcOH. The osmotic minipumps were 
implanted subcutaneously, under short (max 5 min) isoflurane anaesthesia between 11–12 a.m. The infusion of 
AngII at a dose of 350 ng/kg/min has been repeatedly shown to induce hypertension27–29. In our experience, in 
this particular rat strain, higher dosing of AngII results in cerebral haemorrhage. At the end of the AngII infusion, 
tail-cuff plethysmography was used to verify the magnitude of high blood pressure in the rats that were instru-
mented with pO2 telemeters.
Thirteen rats were instrumented with pO2 telemeters (cortex n = 6, medulla n = 7) and underwent AngII 
infusions as described above. In addition, in second set of 16 animals (cortex n = 5, medulla n = 6, MAP n = 5), 
the AT1 receptor blocker losartan (300 mg/L) was added to the drinking water after 6 days of AngII infusion to 
measure the effect of blood pressure normalisation on pO2. The duration of losartan treatment was 48 hours.
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Chronic AngII infusion and hydralazine. In a third set of experiments, rats were instrumented with blood 
pressure (n = 3) or pO2 telemeters (medulla, n = 3), and the peripheral vasodilator hydralazine was added to the 
drinking water and/or subcutaneously injected to give a dose of 5–25 mg/kg/day. Hydralazine was given either 
for 24 hours during AngII infusion to confirm blood pressure normalisation, or started one day before AngII 
infusion to investigate any blood pressure independent effects of AngII on medullar pO2.
Terminal experiments. Renal function was assessed in rats (n = 18) after 8 days of AngII infusion as 
described previously30 and compared with age-matched controls (n = 8). In short, rats were anesthetised 
with 60 mg/kg ip pentobarbital sodium and artificially ventilated (UNO, Zevenaar, the Netherlands). Plasma 
was collected from the femoral artery and urine was collected from the bladder, during infusion of inulin and 
para-aminohippuric acid, to calculate glomerular filtration rate (GFR) and renal plasma flow (RPF), respectively. 
During this experiment MAP was measured via a fluid filled catheter inserted via the femoral artery. Sodium 
contents were measured by flame photometry to obtain tubular sodium reabsorption (TNa) and fractional TNa 
(FTNa) was calculated. Urine samples were also used for assessment of proteinuria. At the end of the renal func-
tion measurements study, kidneys, heart, and thoracic aorta were collected and weighted.
Histology. Right kidneys were fixed for 24 hours in 10% formalin and embedded in paraffin. Slides (3 µm) 
were stained with periodic acid Schiff (PAS). These kidney sections were scored for glomerulosclerosis and 
tubulo-interstitial damage. Of every section fifty glomeruli were divided in five groups of severity (0–4). The 
percentage of glomeruli with a severity score between 2–4 are depicted in Table 1. Tubulo-interstitial damage 
was analyzed for infiltrate, fibrosis and atrophy. Per section twenty areas of tubulo-interstitium were given a score 
between 0 and 5. Mean values are depicted in Table 1. The AngII group was composed of 8 rats with proteinuria 
closest to the median value of the entire AngII group (n = 18). Analysis was performed by an experienced tech-
nician in a blinded manner.
Data analysis. Original pO2 data were recorded in nA by carbon paste electrodes attached to oxygen telem-
eters at 4 Hz. The off-set value was determined post-mortem, and subtracted from the original pO2 data. Baseline 
(nA) values were determined during 5 days before AngII infusion and set at 100% (Figs 1 and 2). Artefacts were 
removed when the 1st order derivative exceeded a threshold of 5 nA/s, as described15. Telemetry data over 1-h 
(AngII + losartan) and 6-h (AngII) periods are expressed as averages ± SEM. On longitudinal pO2 data one-way 
ANOVA for repeated measures was performed followed by a Tukey test. To specify the relation between MAP 
and pO2, the variations in MAP with those occurring in pO2 during baseline and AngII infusion were com-
pared. This was done by pairing the mean pO2 and the mean MAP data in matched periods of 15 min. during 
a baseline period (mean from day −4 to −1) and during AngII infusion (day 3 to 6). Slopes of correlation were 
compared with analysis of covariance (ANCOVA). Circadian rhythmicity of MAP and renal pO2 was quantified 
as described24. The fitted cosine was quantified by the following parameters; mesor (circadian rhythm-adjusted 
mean), amplitude (half the difference between peak and nadir) and acrophase (peaktime). These parameters are 
shown as median with confidence interval (Table 2). Time is expressed as Zeitgeber (ZT), wherein start of lights 
on phase is at ZT0.
Control AngII P
N 8 18
Final body weight (g) 413 ± 14 408 ± 9 NS
MAP (mmHg) 110 ± 6 134 ± 5 <0.05
GFR (µl/min/100 g) 753 ± 42 513 ± 37 <0.01
RPF (µl/min/100 g) 2492 ± 183 1961 ± 121 <0.05
Hematocrit (%) 46 ± 1 48 ± 1 NS
RVR (MAP/RBF/100 g) 25 ± 1 36 ± 4 <0.05
Filtration Fraction 0.31 ± 0.01 0.26 ± 0.01 <0.05
TNa (µmol/min) 446 ± 26 307 ± 41 <0.01
FTNa (%) 0.59 ± 0.01 0.59 ± 0.02 NS
Thoracic aorta weight (mg/100 g bw) 10.7 ± 0.3 17.0 ± 0.7 <0.001
Proteinuria (mg/day) 21 ± 3 43 ± 7 <0.01
N 8 8
Glomerulosclerosis (%) 6 ± 2 10 ± 3 NS
Infiltrate (tubule) 0.11 ± 0.03 0.11 ± 0.04 NS
Fibrosis (tubule) 0.10 ± 0.02 0.30 ± 0.04 <0.001
Atrophy (tubule) 0.03 ± 0.01 0.17 ± 0.04 <0.01
Table 1. Renal hemodynamics (under pentobarbital anesthesia) and renal injury scores after 8 days of 
angiotensin II (AngII) infusion in rats. MAP: mean arterial pressure, GFR: glomerular filtration rate, RPF: renal 
plasma flow, RVR: renal vascular resistance, RBF: renal blood flow, TNa: tubular sodium reabsorption, FTNa: 
fractional tubular sodium reabsorption. Data are expressed as mean ± SEM. An unpaired Student’s t-test was 
performed to determine p-values.
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Figure 1. Cortical and medullary oxygenation (pO2) and mean arterial pressure (MAP) during 8 days of 
angiotensin II (AngII) infusion. Osmotic minipumps were implanted to start 350 ng/kg/min AngII infusion 
(dashed line). Telemetric recordings of cortical (closed circles, n = 6) and medullary (open circles, n = 7) pO2 
were recorded continuously. Values are expressed as a percentage of the baseline period before AngII infusion. 
MAP was determined by telemetry (dots, n = 5) in another subset of animals. Data is presented as mean of 6 h 
averages ± SEM. *p ≤ 0.05 in medulla, †p ≤ 0.05 in cortex, **p ≤ 0.01, all vs. baseline.
Figure 2. Chronic angiotensin II (AngII) infusion and hydralazine. (A) Cortical (n = 6, closed circles) and 
medullary (n = 7, open circles) oxygenation (pO2) and mean arterial pressure (MAP) (n = 5, dots) during the 
early phase of AngII infusion. Osmotic minipumps were implanted to start 350 ng/kg/min AngII infusion 
(dashed line). Values are expressed as a percentage of the baseline period before AngII infusion. Data is 
presented as mean of 1 h averages ± SEM. (B) Medullary (n = 3) pO2 during hydralazine administration 
(5–25 mg/kg/day) only or in combination with AngII infusion (350 ng/kg/min). Data is presented as mean of 1 h 
averages ± SD. Telemetric recordings were recorded continuously. (A,B) were derived from different subsets of 
animals.
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Results
AngII infusion. In the group instrumented with the pressure telemeter baseline MAP was 97 ± 8 mmHg. 
A sustained increase in MAP was observed from 6 h onwards after the start of the subcutaneous infusion of 
AngII. The hypertensive response was maintained throughout the full treatment period rising to maximally 
150 ± 18 mmHg in rats instrumented with pressure telemeters (Fig. 1). SBP, measured in rats instrumented with 
oxygen telemeters, increased from 112 ± 3 to 178 ± 14 mmHg (p < 0.01). This contrasts with the transient reduc-
tions that occurred in cortical and medullary pO2 levels. Renal parenchymal oxygenation started to decrease after 
10 ± 2 h in cortex and 6 ± 1 h in medulla (cortex vs. medulla, p = 0.05) and effects were normalised after 26 ± 3 h 
from the start of the infusion, in both regions (Fig. 2A). Maximal reductions in cortical and medullary pO2 
(compared to baseline) were 18 ± 2% and 17 ± 6%, respectively. Cortical and medullary pO2 levels did not exceed 
baseline variations during the remaining AngII infusion period (Fig. 1). AngII infusion did have hemodynamic 
effects. GFR and RPF were reduced after 8 days in AngII infused animals compared to healthy controls (p < 0.01, 
p < 0.05, respectively), and TNa was proportionately reduced, so that FTNa remained constant. Proteinuria and 
MESOR Con MESOR AngII
Amplitude 
Con
Amplitude 
AngII
Acrophase Con 
(ZT h)
Acrophase AngII 
(ZT h)
Oxygenation Cortex (%, N = 6) 100.0 (99.3–100.7) 100.0 (99.4–100.6) 5.8 (4.7–6.8) 3.6 (2.6–4.6)* 16.9 (16.3–17.4) 18.8 (17.2–20.5)
Oxygenation Medulla (%, N = 7) 100.0 (98.8–101.2) 100.0 (98.9–101.1) 4.9 (3.6–6.3) 3.5 (2.0–4.9) 16.9 (16.0–17.7) 19.4 (17.5–21.4)
MAP (mmHg, N = 5) 95.5 (94.6–95.8) 145.4 (141.8–149.1) 1.6 (0.8–2.4) 5.5 (0.3–10.6) 18.9 (17.6–20.2) 14.1 (11.7–16.4)*
Table 2. Circadian rhythmicity of mean arterial pressure (MAP) and renal oxygenation (pO2) during 
angiotensin II (AngII) infusion. Data were analyzed by cosinor analysis (period = 24 h), lighting schedule; 
lights-on at 6am (ZT0), and lights-off at 6 pm (ZT12). MESOR: Circadian rhythm-adjusted mean, Acrophase: 
Peak time of cosine function. (median, 95% CI), *p < 0.05 vs. Control data obtained from Emans et al. 2017.
Figure 3. Renal morphology. Representative photomicrographs of periodic acid Schiff stained renal sections 
of control (Con, left) and angiotensin II-infused (AngII, right) rats. Mild fibrosis was observed in the cortex of 
AngII treated rats.
Figure 4. Relation between mean arterial pressure (MAP) and oxygenation (pO2) in cortex and medulla. In 
matched periods of 15 min. mean pO2 and mean MAP were paired during a baseline period (day -4 to -1, open 
circles) and during angiotensin II (AngII) infusion (day 3 to 6, closed circles). The characteristic association 
between MAP and pO2, observed during control conditions, disappeared in both cortex and medulla during 
AngII infusion. ANCOVA: p < 0.001 vs. baseline.
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mild renal damage were observed in AngII infused rats (Table 1 and Fig. 3). During the baseline period MAP 
and pO2 were related, in both cortex and medulla. During AngII infusion, the association between MAP and pO2 
disappeared in the cortex and medulla (ANCOVA: p < 0.001 vs. baseline, Fig. 4).
AT1 receptor blockade. When losartan was added to the drinking water MAP fell to near baseline values 
within 12 hours (Fig. 5). Cortical and medullary pO2 increased to 121 ± 7% and 125 ± 7% (compared to 24 h 
prior to losartan, p < 0.05) during the same time frame. However, these increases in pO2 levels were not sustained 
significantly after 20 h during losartan administration, despite persistent normalised MAP.
Chronic AngII infusion and hydralazine. Hydralazine normalised blood pressure from 122 ± 15 to 
101 ± 8 mmHg at a dose of 5–25 mg/kg/day. In rats that were equipped with oxygen telemeters in the renal medulla the 
hydralazine infusion was started one day before the AngII infusion. The data (Fig. 2B) show that average 24 hours pO2 
are comparable to the baseline period and also do not change during the first 24 hours of the AngII infusion (Fig. 2).
Circadian rhythm during AngII infusion. 15-min averaged data collected during day 3, 4, 5, and 6 of 
AngII infusion were used to calculate the acrophase, nadir, and amplitude of the circadian profile of oxygenation 
and MAP. In comparison to previously published control data, a significant circadian profile of MAP was intact in 
AngII infused rats. The MAP acrophase had shifted (from 18.9ZT to 14.1ZT). In both cortex and medulla, a sig-
nificant circadian pattern pO2 was present in AngII infused rats with an amplitude of 3.6% [2.6, 4.6%] and 3.5% 
[2.0, 4.9%], respectively. However, compared to control data, cortical and medullar pO2 rhythms tended to phase 
shift, as indicated by the delayed acrophases (from 16.9ZT to 18.8 and 19.4 ZT). In the cortex, the amplitude of 
pO2 rhythmicity was slightly blunted compared to control (p < 0.05). In the medulla, a similar tendency can be 
observed, but this was not significant (Table 2).
Discussion
The main new finding of this study is that renal cortical and medullary tissue oxygenation only transiently 
decreases during the induction of high blood pressure with AngII. Thus, in this experimental setting kidney 
oxygenation may be more dynamic than previously thought.
While the MAP response in our animals was comparable to values obtained in previous studies using similar 
doses of AngII27–29, the recorded changes in tissue oxygenation are surprising. Decreased oxygenation in cortex 
and medulla was only observed during the first 26 hours of AngII infusion. The timing of the pO2 nadir corre-
sponds with the delay observed in Cyp1a1-Ren2 rats when the endogenous AngII production was activated15. 
When effects of AngII were blocked by an AT1 receptor antagonist cortical and medulla pO2 again increased only 
transiently, despite persistent normalisation of MAP. Together, these observations do not confirm our hypothesis 
that from an early point of time a reduction in renal oxygenation is the major factor involved in AngII induced 
renal damage. Our data rather suggest that adaptation occurs that restores pO2 levels. This adaptation was proba-
bly MAP independent and occurred within the first 24 hours.
The initial (first 20–30 hours) effects of AngII on oxygenation differ from those observed in the later phase (even-
tually leading to the development of renal injury). The declining oxygenation levels during the first 20 hours of 
AngII infusion are likely to be related to a temporary imbalance between oxygen consumption and supply. This 
data is consistent with intrarenal AngII infusion in dogs, wherein RBF decreased during the first 24 hours only31. 
This supports the idea that the initial dip in pO2 during AngII infusion is caused by a decrease in oxygen delivery. 
This is based on previous acute and longitudinal studies in awake animals, that showed that there is an immediate 
decrease in RBF after AngII infusion32,33. Because autoregulatory mechanisms relatively preserve the GFR from 
Figure 5. Cortical and medullary oxygenation (pO2) and mean arterial pressure (MAP) during angiotensin II 
(AngII) infusion plus oral losartan for 48 hours. Losartan was added to the drinking water (300 mg/L, dashed 
line). Telemetric measurements of cortical (closed circles) and medullary (open circles) pO2 were recorded 
continuously. Values are expressed as a percentage of the 12h-period before losartan. MAP was determined 
telemetrically (dots) in another subset of animals. Data is presented as mean of 1 h averages ± SEM. *p ≤ 0.05 in 
medulla, †p ≤ 0.05 in cortex, **p ≤ 0.01, all vs. the average of the 12 hours prior to losartan (set point).
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such a reduction, this may result in a mismatch between oxygen consumption and delivery because the filtered load 
is less reduced than RBF is. This phenomenon on its own causes a pO2 drop. At first, while the pressure effects are 
rather limited, AngII does limit renal blood flow, while the increased production of vasodilatory prostaglandins and 
nitric oxide is insufficient to overcome the flow limiting effects of AngII31,34. In the second phase (after the first day) 
the progressive rise in MAP may facilitate pressure-natriuresis by deactivation of Na+ channels28. So, at the start of 
AngII infusion Na+ reabsorption is activated, but once blood pressure rises, this is suppressed35. In agreement, we 
found TNa to be lower in the 8-day infused animals and GFR was proportionately reduced, so that FTNa remained 
constant. This indicates that a new homeostatic balance is accomplished between directly AngII-induced responses 
and compensatory hypertension-driven mechanisms. Therefore, pO2 levels remain constant between day 2 and 8 
in this study. Renal metabolism is largely determined by Na+ reabsorption36,37. The proximal tubule is the most cost 
effective Na+ reabsorption site in terms of energy requirements38. Increasing Na+ reabsorption in less efficient seg-
ments of the tubule can potentially reduce pO2. Na+ reabsorption was reported to be enhanced in the distal nephron 
of mice when circulating angiotensin II is increased for 2 weeks39. Similarly, increased distal nephron reabsorption 
was reported in Cyp1a1-Ren2 rats 4 days after inducing RAS activity40. The potential alterations and shift of Na+ 
reabsorption to less efficient areas of the tubule do not seem to be reflected in pO2 at least until day 8 in our study.
An increased efficiency of oxygen use for Na+ reabsorption is not likely to be involved, because oxygen effi-
ciency was found to be lowered in AngII infused animals19,41. All in all, our data suggest that hypoxia due to 
decreased delivery by AngII infusion persists in the early phase and is lost when intrarenal blood flow increases in 
both cortex and medulla. Indeed, according to current observations, renal oxygen levels normalised once MAP 
was already progressively increasing. Since our current experiment lasted only 8 days it does not preclude that 
renal hypoxia may return when kidney damage progresses over time. The injury response to activation of the 
RAS (genetic or pharmacological) depends on genetic background of the rat or mouse used. Some strains sustain 
almost no injury despite the same level of hypertension. This is shown for the Cyp1a1-Ren2 rat20 and also for the 
AngII infusion model29,42. Therefore, we need to limit our conclusions to the mild renal injury scores and protein-
uria, regarding the effect of AngII on renal oxygenation.
Blockade of AngII increased cortical and medulla pO2 also only transiently in our animals. This suggests 
that oxygenation adapts within 30 hours towards hemodynamic changes induced by AT1 receptor signalling. 
Unchanged cortical pO2 was also found in anaesthetised rats after one week of losartan, despite a reduction in 
MAP43. When intrarenal AngII was discontinued in conscious dogs, a transient increase in RBF was observed, 
which suggest that increased oxygen delivery caused the pO2 response31. In CKD patients, kidney oxygenation 
was improved by RAS inhibitors, directly and chronically44. The residual oxygen increase during AT1 blockade 
could be due to the vasodilator effect of AT2, which is still stimulated45,46.
Various compensatory mechanisms could act chronically after AngII infusion (as opposed to the direct increase 
in nitric oxide and prostaglandins). Previously it has been demonstrated that AngII infusion stimulates the produc-
tion of erythropoietin47. In our data, a trend towards increased haematocrit in AngII could reflect such adaptation 
to hypoxia. This should be subject of further study. The normalisation effects on cortical and medullary oxygenation 
observed in this study are probably blood pressure independent because the relation between MAP and pO2 was 
lost during AngII infusion. Nevertheless, these experiments cannot completely exclude the contribution of MAP 
considering that during AngII infusion it is far higher than during baseline. However, in rats made hypertensive by 
NOS inhibition the relation between MAP and pO2 was maintained in the cortex even though MAP was higher than 
during AngII infusion48. In addition, normalisation of perfusion pressure by suprarenal clamping in the 2-kidney, 
1-clip rat model, did not significantly change the pO2 in the cortex of the unclipped kidney49. This perhaps suggests 
that normalisation of pO2 in our AngII-induced model is stimulus and not pressure-dependent and may be regu-
lated by nitric oxide and AT2 receptors which are responsible for maintaining oxygenation in the 2-kidney, 1-clip 
kidneys49. We conclude that the initial dip of medullar pO2 after starting AngII is at least partially dependent on the 
AngII induced increase in blood pressure as this dip of medullar pO2 is no longer observed when AngII is given 
during a hydralazine regime which keeps blood pressure at baseline levels.
The impact of chronic AngII on renal oxygenation, in this study, is reflected by a blunted amplitude of cortical 
oxygenation compared to control data24 and a shift of renal (cortex and medulla) oxygenation acrophase from 2 h 
before the MAP peak to 5 h after the MAP peak. It is possible that the MAP rhythm could shift even more over time. 
In transgenic Sprague-Dawley rats that overexpress the mouse Ren-2 renin gene constitutively, the blood pressure 
rhythm is shifted even more and highest values occur during the first hours of the lights on period, with minimal 
locomotor activity. Renal hemodynamics were only mildly affected50. While plasma AngII levels display also a circa-
dian rhythmicity in healthy individuals and hypertensive patients there is no correlation to blood pressure51.
There are some limitations to our study that merit discussion. First, considering some technical aspects, we 
did not perform renal blood flow measurements as combining them with intrarenal oxygenation is technically 
not yet feasible. For similar reasons, the recording of MAP and renal oxygenation were performed in separate 
animals. Future technical developments may enable combining these measurements, which is important to iden-
tify the mechanisms at stake. Ideally telemetry-based oxygenation measurements need to be delivered in absolute 
values; now the technique allows only a relative calibration.
Secondly, as to the generalizability of our findings, the changes in our study occurred in the absence of sig-
nificant glomerulosclerosis (although we identified some tubular changes accompanying reduced GFR and pro-
teinuria). It is plausible that when interstitial fibrosis becomes evident after longer periods of AngII infusion, i.e. 
after at least two weeks, renal oxygenation may well fall. Indeed, and in contrast with the current 8-day AngII 
infusion study, Welch et al. showed decreased oxygen levels in cortex and medulla in barbiturate anesthetised 
Wistar-Kyoto rats after 12–13 days of AngII infusion19. This could reflect loss of adaptation due to progressive 
injury, but it is also possible that anaesthesia impacts on adaptation. During first-day52 and prolonged53 infusion 
of AngII, Mezies et al. showed a disrupted oxygenation gradient, detected by BOLD MRI, that was character-
ised by high and low areas of pO2 within the rat kidney of the F344/NCrl strain. Acute pressor doses of AngII 
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increased peritubular ischemia54. In humans, a 15 mmHg increase in MAP by AngII simultaneously decreased 
cortical oxygenation, which was attributed to decreased perfusion11,12. Infusion of a subpressor dose of AngII had 
no impact on medullar flow or pO2, measured by microelectrodes in anesthetised Sprague-Dawley rats55. That 
pO2 can be maintained along a physiological range of RBF was also shown in rabbits56.
In summary, the reported longitudinal measurements of cortical and medullary renal pO2 in conscious rats 
showed that AngII infusion at levels that induce hypertension do not cause sustained renal hypoxia before the 
onset of renal injury. Oxygenation was transiently decreased during the first day of AngII infusion, while normal-
isation occurred when MAP rose progressively.
Data Availability
The data that support the findings of this study are available from the authors upon reasonable request.
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